Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Magnetic Resonance Imaging

Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Modular Synthesis of Peptide-Based Single- and Multimodal Targeted Molecular Imaging Agents.

ACS applied bio materials·2022

Same author

Modular Synthesis of DOTA-Metal-Based PSMA-Targeted Imaging Agents for MRI and PET of Prostate Cancer.

Chemistry (Weinheim an der Bergstrasse, Germany)·2019

查看所有相关文章

Search research articles

相关实验视频

Updated: Jun 24, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

自组装基高放松性向MRI对比剂自组装基高放松性向MRI对比剂

Andrew M O'Brien¹, Griffin C Pileski¹, Matthew P Henry¹

¹School of Chemistry and Materials Science, Rochester Institute of Technology, Rochester, NY-14623.

|June 3, 2024

概括

具有Gd-DOTA的自组合基MRI对比剂通过Fmoc-基相互作用显著增强放松性 (r1). 这种自组装策略为开发有针对性,高放松度的药物来改进MRI提供了一种多功能方法.

关键词:

这就是为什么MRI是MRI.癌症癌症癌症癌症癌症这是一种类.自动组装的自动组装机定位目标定位目标定位目标

更多相关视频

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

相关实验视频

Last Updated: Jun 24, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

科学领域:

生物医学工程生物医学工程
材料科学材料科学材料科学
放射化学放射化学是指辐射化学.

背景情况:

磁共振成像 (MRI) 的对比剂通过改变水质子的放松时间来提高图像质量.
加多-DOTA (Gd-DOTA) 酸盐是常见的MRI对比剂,但它们的放松性可能是有限的.
基于的药物的自我组装提供了一种扩大放松性的策略.

研究的目的:

为了研究自我组装对基于的MRI对比剂的放松性 (r1) 的影响.
探索序列,离子强度和生物介质对药剂性能的影响.
使用自组装方法开发有针对性的高放松度MRI对比剂.

主要方法:

合成各种包含Fmoc和Gd-DOTA的二和三.
在不同条件下 (离子强度,缓冲区,血清) 评估放松度 (r1) 和临界聚合度 (CAC).
通过将PSMA结合连体 (DCL) 与基架结合,设计和合成向剂.

主要成果:

含有的Fmoc-三的自我组装显著增加了r1值,从3.5-7.4增加到13.2-16.9mM-1s-1每Gd.
发现临界聚合度 (CACs) 取决于度,在缓冲剂中为0.22-2.59mM,在胎儿牛血清 (FBS) 中为<25μM.
向药物表现出高的r1值 (13.5-14.8mM-1s-1在缓冲区,11.2-11.9mM-1s-1在FBS) 与低的CAC在FBS.

结论:

自组装是一种有效的策略,可以显著提高基于Gd-DOTA的MRI对比剂的放松性.
开发的基于的药物在FBS.等生物相关介质中保持高放松性和低CAC.
这项工作提供了一个广泛适用的途径,通过后期结合来创建有针对性的,高放松度的MRI对比剂.